-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Assumes AbbVie at Neutral, Raises Price Target to $240

Benzinga·01/07/2026 13:54:47
语音播报
UBS analyst Michael Yee assumes AbbVie (NYSE:ABBV) with a Neutral rating and raises Price Target to $240.